{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:04:35Z","timestamp":1772132675782,"version":"3.50.1"},"reference-count":65,"publisher":"FapUNIFESP (SciELO)","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. braz j urol."],"DOI":"10.1590\/s1677-5538.ibju.2020.0681","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T20:44:56Z","timestamp":1633121096000},"page":"1228-1242","source":"Crossref","is-referenced-by-count":18,"title":["The role of immunotherapy in advanced renal cell carcinoma"],"prefix":"10.1590","volume":"47","author":[{"given":"Erc\u00edlia Rita","family":"Mondlane","sequence":"first","affiliation":[{"name":"ESTeSC, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4304-7023","authenticated-orcid":false,"given":"Pedro","family":"Abreu-Mendes","sequence":"additional","affiliation":[{"name":"Centro Hospital Universit\u00e1rio de S\u00e3o Jo\u00e3o, Portugal; Universidade do Porto, Portugal"}]},{"given":"Diana","family":"Martins","sequence":"additional","affiliation":[{"name":"ESTeSC, Portugal; Universidade de Coimbra, Portugal; Universidade de Coimbra, Portugal; Centro Acad\u00e9mico Cl\u00ednico de Coimbra, Portugal; Universidade do Porto, Portugal"}]},{"given":"Rui","family":"Cruz","sequence":"additional","affiliation":[{"name":"ESTeSC, Portugal"}]},{"given":"Fernando","family":"Mendes","sequence":"additional","affiliation":[{"name":"ESTeSC, Portugal; Universidade de Coimbra, Portugal; Universidade de Coimbra, Portugal; Centro Acad\u00e9mico Cl\u00ednico de Coimbra, Portugal"}]}],"member":"530","published-online":{"date-parts":[[2021,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5507\/bp.2015.050","article-title":"Renal cell carcinoma: Review of etiology, pathophysiology and risk factors","volume":"160","author":"Petejova N","year":"2016","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU guidelines on renal cell carcinoma: 2014 update","volume":"67","author":"Ljungberg B","year":"2015","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijscr.2019.10.035","article-title":"Colonic metastasis of renal cell carcinoma following curative nephrectomy: A case report and review of the literature","volume":"65","author":"Suba I\u00d6","year":"2019","journal-title":"Int J Surg Case Rep"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of Renal Cell Carcinoma","volume":"75","author":"Capitanio U","year":"2019","journal-title":"Eur Urol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2174\/1874467208666150716121116","article-title":"Current Immunotherapies for Renal Cell Carcinoma","volume":"9","author":"Al-Marrawi MY","year":"2016","journal-title":"Curr Mol Pharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","article-title":"Advances in cancer immunotherapy 2019 - latest trends","volume":"38","author":"Kruger S","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.7150\/thno.37194","article-title":"Peptide-based materials for cancer immunotherapy","volume":"9","author":"Zhang L","year":"2019","journal-title":"Theranostics"},{"key":"ref9","series-title":"Can J Physiol Pharmacol","first-page":"3","volume":"96","year":"2018"},{"key":"ref10","first-page":"194","article-title":"Immunotherapy of cancer","volume":"46","author":"Trapani JA","year":"2017","journal-title":"Aust Fam Physician"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley RS","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40164-017-0081-6","article-title":"Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today\u2019s treat-to-target era","volume":"6","author":"Zhang L","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1080\/21645515.2016.1212794","article-title":"Immunotherapy of advanced renal cell carcinoma: Current and future therapies","volume":"12","author":"Gill D","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3389\/fimmu.2018.02905","article-title":"Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy","volume":"9","author":"Mortara L","year":"2018","journal-title":"Front Immunol"},{"key":"ref15","article-title":"Development of a novel class of interleukin-2 immunotherapies for metastatic cancer","volume":"149","author":"Boyman O","year":"2019","journal-title":"Swiss Med Wkly"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/UA.UA_166_17","article-title":"New treatment modalities with vaccine therapy in renal cell carcinoma","volume":"11","author":"S\u00f6nmez MG","year":"2019","journal-title":"Urol Ann"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3389\/fimmu.2018.00610","article-title":"Combination Immunotherapy: Taking Cancer Vaccines to the Next Level","volume":"9","author":"Grenier JM","year":"2018","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2018.10.008","article-title":"Biomaterials for vaccine-based cancer immunotherapy","volume":"292","author":"Zhang R","year":"2018","journal-title":"J Control Release"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.3389\/fimmu.2018.03109","article-title":"Therapeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation","volume":"9","author":"Kartikasari AER","year":"2019","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coi.2017.07.003","article-title":"Cancer immunotherapy: moving forward with peptide T cell vaccines","volume":"47","author":"Kumai T","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4111\/icu.2017.58.4.220","article-title":"Novel immunotherapy in metastatic renal cell carcinoma","volume":"58","author":"Cho YH","year":"2017","journal-title":"Investig Clin Urol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-015-0055-3","article-title":"Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results","volume":"3","author":"Amin A","year":"2015","journal-title":"J Immunother Cancer"},{"key":"ref23","article-title":"Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens","volume":"2018","author":"Pan RY","year":"2018","journal-title":"J Immunol Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S1470-2045(16)30408-9","article-title":"IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"17","author":"Rini BI","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3322\/caac.21411","article-title":"Treatment of renal cell carcinoma: Current status and future directions","volume":"67","author":"Barata PC","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"ref26","first-page":"5935","article-title":"Monoclonal Antibodies for the Treatment of Cancer","volume":"37","author":"Pento JT","year":"2017","journal-title":"Anticancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"150927","DOI":"10.1016\/j.soncn.2019.08.006","article-title":"An Overview of Monoclonal Antibodies","volume":"35","author":"Bayer V","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.47102\/annals-acadmedsg.V47N9p381","article-title":"Cancer Immunotherapy - The Target is Precisely on The Cancer and Also Not","volume":"47","author":"Koo SL","year":"2018","journal-title":"Ann Acad Med Singapore"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1982423","DOI":"10.1155\/2018\/1982423","article-title":"Immune Checkpoint Inhibitors to Treat Malignant Lymphomas","volume":"2018","author":"Witkowska M","year":"2018","journal-title":"J Immunol Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdx151","article-title":"Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions","volume":"28","author":"Atkins MB","year":"2017","journal-title":"Ann Oncol"},{"key":"ref31","series-title":"Immunother. Sarcoma","first-page":"125","volume-title":"Immune Checkpoint Inhibitors in Sarcoma","volume":"42","author":"D\u2019Angelo SP","year":"2019"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon KM","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40259-017-0257-y","article-title":"Therapeutic Cancer Vaccines: How Much Closer Are We?","volume":"32","author":"McNeel DG","year":"2018","journal-title":"BioDrugs"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11912-019-0851-x","article-title":"Novel Immunotherapy Combinations","volume":"21","author":"Bashir B","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3389\/fimmu.2018.02166","article-title":"The Potential of CAR T Cell Therapy in Pancreatic Cancer","volume":"9","author":"Akce M","year":"2018","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"Sansom DM. CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan B","year":"2018","journal-title":"Blood"},{"key":"ref37","series-title":"C\u00e9lulas presentadoras de ant\u00edgeno profesionales: c\u00e9lulas dendr\u00edticas Uno de los importantes nexos entre la respuesta inmuni-","first-page":"307","author":"Rizzo M","year":"2016"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: Basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad A","year":"2019","journal-title":"J Cell Physiol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/cancers11071000","article-title":"Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma","volume":"11","author":"Chen VJ","year":"2019","journal-title":"Cancers (Basel)"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"100663","DOI":"10.1016\/j.jbior.2019.100663","article-title":"Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy","volume":"75","author":"Arranz-Nicol\u00e1s J","year":"2020","journal-title":"Adv Biol Regul"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1590\/s1677-5538.ibju.2017.0315","article-title":"Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials","volume":"44","author":"Wei C","year":"2018","journal-title":"Int Braz J Urol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-017-0307-5","article-title":"Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry","volume":"5","author":"Curti B","year":"2017","journal-title":"J Immunother Cancer"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s12885-015-1675-1","article-title":"Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan","volume":"15","author":"Eto M","year":"2015","journal-title":"BMC Cancer"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/0284186X.2018.1433324","article-title":"A randomized phase II trial of interleukin-2 and interferon-\u03b1 plus bevacizumab versus interleukin-2 and interferon-\u03b1 in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1","volume":"57","author":"Donskov F","year":"2018","journal-title":"Acta Oncol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer RJ","year":"2015","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program","volume":"7","author":"Verzoni E","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.3747\/co.26.4595","article-title":"Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"26","author":"Stukalin I","year":"2019","journal-title":"Curr Oncol"},{"key":"ref48","first-page":"284","article-title":"A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma","volume":"12","author":"Kimura M","year":"2020","journal-title":"Mol Clin Oncol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","article-title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","volume":"6","author":"Amin A","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study","volume":"35","author":"Hammers HJ","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jjco\/hyz132","article-title":"Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up","volume":"50","author":"Tomita Y","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","volume":"7","author":"Rini BI","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini BI","year":"2019","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins MB","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors","volume":"38","author":"Taylor MH","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1590\/s1677-5538.ibju.2017.0500","article-title":"Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma","volume":"45","author":"Wang B","year":"2019","journal-title":"Int Braz J Urol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s40425-019-0746-2","article-title":"Avelumab monotherapy as first-line or second-line tre atment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial","volume":"7","author":"Vaishampayan U","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri TK","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref59","series-title":"Kidney cancer","first-page":"268","volume":"16","author":"Primo N","year":"2017","edition":"Second Eds."},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer RJ","year":"2019","journal-title":"N Engl J Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini BI","year":"2019","journal-title":"Lancet"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott DF","year":"2018","journal-title":"Nat Med"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1590\/s1677-5538.ibju.2018.0271","article-title":"Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications","volume":"45","author":"Kobayashi M","year":"2019","journal-title":"Int Braz J Urol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1590\/s1677-5538.ibju.2019.0560","article-title":"Preoperative serum total cholesterol is a predictor of prognosis in patients with renal cell carcinoma: a meta- analysis of observational studies","volume":"46","author":"Li B","year":"2020","journal-title":"Int Braz J Urol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bju.14461","article-title":"Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme","volume":"123","author":"De Giorgi U","year":"2019","journal-title":"BJU Int"}],"container-title":["International braz j urol"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ibju\/v47n6\/1677-6119-ibju-47-06-1228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T23:52:34Z","timestamp":1673394754000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1677-55382021000601228&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["S1677-55382021000601228"],"URL":"https:\/\/doi.org\/10.1590\/s1677-5538.ibju.2020.0681","relation":{},"ISSN":["1677-6119","1677-5538"],"issn-type":[{"value":"1677-6119","type":"electronic"},{"value":"1677-5538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}